Reported since 1962 and repeated many times in unregulated clinics, but the evidence base is weak. Rigorous trials have been slow, partly because the compound is controlled in many jurisdictions and partly because a treatment given once does not fit the commercial model that funds drug development. Meanwhile ibogaine is cardiotoxic, prolongs the QT interval, and deaths have occurred where screening was absent.
What would resolve this Adequately powered controlled trials with cardiac monitoring. The question is included here rather than left to medicine because the answer bears on the plant: demand from outside Gabon is already driving overharvesting of wild stands of a slow growing species that a religion depends on.
OpenPharmacology, addiction medicine, cardiology, conservation biologyJames W. Fernandez, Bwiti: An Ethnography of the Religious Imagination in Africa